These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 31026118)

  • 1. Additive value of diffusion-weighted MRI in the I-SPY 2 TRIAL.
    Li W; Newitt DC; Wilmes LJ; Jones EF; Arasu V; Gibbs J; La Yun B; Li E; Partridge SC; Kornak J; ; Esserman LJ; Hylton NM
    J Magn Reson Imaging; 2019 Dec; 50(6):1742-1753. PubMed ID: 31026118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion-weighted MRI Findings Predict Pathologic Response in Neoadjuvant Treatment of Breast Cancer: The ACRIN 6698 Multicenter Trial.
    Partridge SC; Zhang Z; Newitt DC; Gibbs JE; Chenevert TL; Rosen MA; Bolan PJ; Marques HS; Romanoff J; Cimino L; Joe BN; Umphrey HR; Ojeda-Fournier H; Dogan B; Oh K; Abe H; Drukteinis JS; Esserman LJ; Hylton NM;
    Radiology; 2018 Dec; 289(3):618-627. PubMed ID: 30179110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion-weighted imaging in assessing pathological response of tumor in breast cancer subtype to neoadjuvant chemotherapy.
    Liu S; Ren R; Chen Z; Wang Y; Fan T; Li C; Zhang P
    J Magn Reson Imaging; 2015 Sep; 42(3):779-87. PubMed ID: 25580585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the Apparent Diffusion Coefficient in the Prediction of Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer.
    Bufi E; Belli P; Costantini M; Cipriani A; Di Matteo M; Bonatesta A; Franceschini G; Terribile D; Mulé A; Nardone L; Bonomo L
    Clin Breast Cancer; 2015 Oct; 15(5):370-80. PubMed ID: 25891905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Machine Learning With Multiparametric Magnetic Resonance Imaging of the Breast for Early Prediction of Response to Neoadjuvant Chemotherapy and Survival Outcomes in Breast Cancer Patients.
    Tahmassebi A; Wengert GJ; Helbich TH; Bago-Horvath Z; Alaei S; Bartsch R; Dubsky P; Baltzer P; Clauser P; Kapetas P; Morris EA; Meyer-Baese A; Pinker K
    Invest Radiol; 2019 Feb; 54(2):110-117. PubMed ID: 30358693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diffusion-weighted imaging (DWI) with apparent diffusion coefficient (ADC) mapping as a quantitative imaging biomarker for prediction of immunohistochemical receptor status, proliferation rate, and molecular subtypes of breast cancer.
    Horvat JV; Bernard-Davila B; Helbich TH; Zhang M; Morris EA; Thakur SB; Ochoa-Albiztegui RE; Leithner D; Marino MA; Baltzer PA; Clauser P; Kapetas P; Bago-Horvath Z; Pinker K
    J Magn Reson Imaging; 2019 Sep; 50(3):836-846. PubMed ID: 30811717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer using diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging.
    Xu HD; Zhang YQ
    Neoplasma; 2017; 64(3):430-436. PubMed ID: 28253722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of breast cancer phenotype on diagnostic performance of MRI in the prediction to response to neoadjuvant treatment.
    Bufi E; Belli P; Di Matteo M; Terribile D; Franceschini G; Nardone L; Petrone G; Bonomo L
    Eur J Radiol; 2014 Sep; 83(9):1631-8. PubMed ID: 24938669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Alternate
    Partridge SC; Steingrimsson J; Newitt DC; Gibbs JE; Marques HS; Bolan PJ; Boss MA; Chenevert TL; Rosen MA; Hylton NM
    Tomography; 2022 Mar; 8(2):701-717. PubMed ID: 35314635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of ADC Difference Value on Pre-neoadjuvant Chemotherapy MRI for Response Evaluation of Breast Cancer.
    Choi BB
    Technol Cancer Res Treat; 2021; 20():15330338211039129. PubMed ID: 34519583
    [No Abstract]   [Full Text] [Related]  

  • 11. Is simultaneous multi-slice readout-segmented echo-planar imaging valuable for predicting molecular subtypes of breast cancer?
    Li X; Zhu H; Sun K; Chai W; Fu C; Yan F
    Eur J Radiol; 2022 May; 150():110232. PubMed ID: 35259708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contrast-free diffusion MRI multiple index for the early prediction of pathological response to neoadjuvant chemotherapy in breast cancer.
    Zhang L; Ning N; Liang H; Zhao S; Gao X; Liu A; Song Q; Duan X; Yang J; Xie L
    NMR Biomed; 2024 Nov; 37(11):e5176. PubMed ID: 38884131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.
    Li X; Abramson RG; Arlinghaus LR; Kang H; Chakravarthy AB; Abramson VG; Farley J; Mayer IA; Kelley MC; Meszoely IM; Means-Powell J; Grau AM; Sanders M; Yankeelov TE
    Invest Radiol; 2015 Apr; 50(4):195-204. PubMed ID: 25360603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trial.
    Newitt DC; Zhang Z; Gibbs JE; Partridge SC; Chenevert TL; Rosen MA; Bolan PJ; Marques HS; Aliu S; Li W; Cimino L; Joe BN; Umphrey H; Ojeda-Fournier H; Dogan B; Oh K; Abe H; Drukteinis J; Esserman LJ; Hylton NM;
    J Magn Reson Imaging; 2019 Jun; 49(6):1617-1628. PubMed ID: 30350329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triple-negative invasive breast cancer on dynamic contrast-enhanced and diffusion-weighted MR imaging: comparison with other breast cancer subtypes.
    Youk JH; Son EJ; Chung J; Kim JA; Kim EK
    Eur Radiol; 2012 Aug; 22(8):1724-34. PubMed ID: 22527371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab.
    Hsiang DJ; Yamamoto M; Mehta RS; Su MY; Baick CH; Lane KT; Butler JA
    Arch Surg; 2007 Sep; 142(9):855-61; discussion 860-1. PubMed ID: 17875840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Systemic Therapy in Breast Cancer: Association of Contrast-enhanced MR Imaging Findings, Diffusion-weighted Imaging Findings, and Tumor Subtype with Tumor Response.
    Santamaría G; Bargalló X; Fernández PL; Farrús B; Caparrós X; Velasco M
    Radiology; 2017 Jun; 283(3):663-672. PubMed ID: 27875106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved discrimination of molecular subtypes in invasive breast cancer: Comparison of multiple quantitative parameters from breast MRI.
    Du S; Gao S; Zhang L; Yang X; Qi X; Li S
    Magn Reson Imaging; 2021 Apr; 77():148-158. PubMed ID: 33309922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative evaluation of breast cancer response to neoadjuvant chemotherapy by diffusion tensor imaging: Initial results.
    Furman-Haran E; Nissan N; Ricart-Selma V; Martinez-Rubio C; Degani H; Camps-Herrero J
    J Magn Reson Imaging; 2018 Apr; 47(4):1080-1090. PubMed ID: 28901594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017.
    De Los Santos JF; Cantor A; Amos KD; Forero A; Golshan M; Horton JK; Hudis CA; Hylton NM; McGuire K; Meric-Bernstam F; Meszoely IM; Nanda R; Hwang ES
    Cancer; 2013 May; 119(10):1776-83. PubMed ID: 23436342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.